A real-world descriptive study of screening practices for hydroxychloroquine retinopathy in Japan using an insurance claims database
Abstract Since 2015, hydroxychloroquine (HCQ) has been widely used as a standard treatment for systemic lupus erythematosus (SLE) and cutaneous lupus erythematosus (CLE) under the national health insurance system in Japan. However, the status of routine ophthalmological screening for retinopathy, wh...
Saved in:
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Nature Portfolio
2025-04-01
|
| Series: | Scientific Reports |
| Subjects: | |
| Online Access: | https://doi.org/10.1038/s41598-025-96579-2 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849726217556590592 |
|---|---|
| author | Kumiko Kato Kei Shinoda Naoto Yokogawa Takumi Tajima Toshiya Takahashi Mineo Kondo |
| author_facet | Kumiko Kato Kei Shinoda Naoto Yokogawa Takumi Tajima Toshiya Takahashi Mineo Kondo |
| author_sort | Kumiko Kato |
| collection | DOAJ |
| description | Abstract Since 2015, hydroxychloroquine (HCQ) has been widely used as a standard treatment for systemic lupus erythematosus (SLE) and cutaneous lupus erythematosus (CLE) under the national health insurance system in Japan. However, the status of routine ophthalmological screening for retinopathy, which is a notable safety concern of HCQ, remains unclear. In this retrospective study using the nationwide health insurance claims database, we aimed to investigate the status of ophthalmological screening in routine clinical practice in Japan. A total of 2567 patients with SLE or CLE were included in the analysis. The proportion of ophthalmology visits was 88.0% at the initiation of HCQ prescription, decreased to 76.3% after one year, and then remained constant. Moreover, only 50% of the patients underwent spectral-domain optical coherence tomography (SD-OCT) and automated visual field (VF) tests, which are useful for the early detection of HCQ retinopathy-related changes. Importantly, the proportion of ophthalmology visits remained consistently high among patients who visited an ophthalmologist in the previous year, ranging from 77.3% to 90.2%. These findings highlight the need to improve screening adherence and promote regular ophthalmological evaluations, particularly for patients without prior ophthalmology visits, to enhance the early detection of HCQ retinopathy. |
| format | Article |
| id | doaj-art-ce53db3711574d038d66c05b21000ab2 |
| institution | DOAJ |
| issn | 2045-2322 |
| language | English |
| publishDate | 2025-04-01 |
| publisher | Nature Portfolio |
| record_format | Article |
| series | Scientific Reports |
| spelling | doaj-art-ce53db3711574d038d66c05b21000ab22025-08-20T03:10:14ZengNature PortfolioScientific Reports2045-23222025-04-011511910.1038/s41598-025-96579-2A real-world descriptive study of screening practices for hydroxychloroquine retinopathy in Japan using an insurance claims databaseKumiko Kato0Kei Shinoda1Naoto Yokogawa2Takumi Tajima3Toshiya Takahashi4Mineo Kondo5Department of Ophthalmology, Mie University Graduate School of MedicineDepartment of Ophthalmology, Saitama Medical University HospitalDepartment of Rheumatic Diseases, Tokyo Metropolitan Tama Medical CenterJMDC, Inc.Medical Affairs Department, Asahi Kasei Pharma CorporationDepartment of Ophthalmology, Mie University Graduate School of MedicineAbstract Since 2015, hydroxychloroquine (HCQ) has been widely used as a standard treatment for systemic lupus erythematosus (SLE) and cutaneous lupus erythematosus (CLE) under the national health insurance system in Japan. However, the status of routine ophthalmological screening for retinopathy, which is a notable safety concern of HCQ, remains unclear. In this retrospective study using the nationwide health insurance claims database, we aimed to investigate the status of ophthalmological screening in routine clinical practice in Japan. A total of 2567 patients with SLE or CLE were included in the analysis. The proportion of ophthalmology visits was 88.0% at the initiation of HCQ prescription, decreased to 76.3% after one year, and then remained constant. Moreover, only 50% of the patients underwent spectral-domain optical coherence tomography (SD-OCT) and automated visual field (VF) tests, which are useful for the early detection of HCQ retinopathy-related changes. Importantly, the proportion of ophthalmology visits remained consistently high among patients who visited an ophthalmologist in the previous year, ranging from 77.3% to 90.2%. These findings highlight the need to improve screening adherence and promote regular ophthalmological evaluations, particularly for patients without prior ophthalmology visits, to enhance the early detection of HCQ retinopathy.https://doi.org/10.1038/s41598-025-96579-2HydroxychloroquineOphthalmological screeningLupus erythematosusRetinopathySafety |
| spellingShingle | Kumiko Kato Kei Shinoda Naoto Yokogawa Takumi Tajima Toshiya Takahashi Mineo Kondo A real-world descriptive study of screening practices for hydroxychloroquine retinopathy in Japan using an insurance claims database Scientific Reports Hydroxychloroquine Ophthalmological screening Lupus erythematosus Retinopathy Safety |
| title | A real-world descriptive study of screening practices for hydroxychloroquine retinopathy in Japan using an insurance claims database |
| title_full | A real-world descriptive study of screening practices for hydroxychloroquine retinopathy in Japan using an insurance claims database |
| title_fullStr | A real-world descriptive study of screening practices for hydroxychloroquine retinopathy in Japan using an insurance claims database |
| title_full_unstemmed | A real-world descriptive study of screening practices for hydroxychloroquine retinopathy in Japan using an insurance claims database |
| title_short | A real-world descriptive study of screening practices for hydroxychloroquine retinopathy in Japan using an insurance claims database |
| title_sort | real world descriptive study of screening practices for hydroxychloroquine retinopathy in japan using an insurance claims database |
| topic | Hydroxychloroquine Ophthalmological screening Lupus erythematosus Retinopathy Safety |
| url | https://doi.org/10.1038/s41598-025-96579-2 |
| work_keys_str_mv | AT kumikokato arealworlddescriptivestudyofscreeningpracticesforhydroxychloroquineretinopathyinjapanusinganinsuranceclaimsdatabase AT keishinoda arealworlddescriptivestudyofscreeningpracticesforhydroxychloroquineretinopathyinjapanusinganinsuranceclaimsdatabase AT naotoyokogawa arealworlddescriptivestudyofscreeningpracticesforhydroxychloroquineretinopathyinjapanusinganinsuranceclaimsdatabase AT takumitajima arealworlddescriptivestudyofscreeningpracticesforhydroxychloroquineretinopathyinjapanusinganinsuranceclaimsdatabase AT toshiyatakahashi arealworlddescriptivestudyofscreeningpracticesforhydroxychloroquineretinopathyinjapanusinganinsuranceclaimsdatabase AT mineokondo arealworlddescriptivestudyofscreeningpracticesforhydroxychloroquineretinopathyinjapanusinganinsuranceclaimsdatabase AT kumikokato realworlddescriptivestudyofscreeningpracticesforhydroxychloroquineretinopathyinjapanusinganinsuranceclaimsdatabase AT keishinoda realworlddescriptivestudyofscreeningpracticesforhydroxychloroquineretinopathyinjapanusinganinsuranceclaimsdatabase AT naotoyokogawa realworlddescriptivestudyofscreeningpracticesforhydroxychloroquineretinopathyinjapanusinganinsuranceclaimsdatabase AT takumitajima realworlddescriptivestudyofscreeningpracticesforhydroxychloroquineretinopathyinjapanusinganinsuranceclaimsdatabase AT toshiyatakahashi realworlddescriptivestudyofscreeningpracticesforhydroxychloroquineretinopathyinjapanusinganinsuranceclaimsdatabase AT mineokondo realworlddescriptivestudyofscreeningpracticesforhydroxychloroquineretinopathyinjapanusinganinsuranceclaimsdatabase |